Decitabine together with Aclacinomycin/Cytarabine to induce remission in patients with refractory acute myeloid leukemia

Trial Profile

Decitabine together with Aclacinomycin/Cytarabine to induce remission in patients with refractory acute myeloid leukemia

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 May 2012

At a glance

  • Drugs Aclarubicin (Primary) ; Cytarabine (Primary) ; Decitabine (Primary)
  • Indications Myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 May 2012 Planned End Date 29 Feb 2012 added as reported by Chinese Clinical Trial Register record.
    • 21 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top